Rather than blocking ATP hydrolysis or inhibiting all client interactions, targeting dynamic interface regions within the Hsp90–Cdc37–kinase axis allows for context-specific disruption, effectively modulating oncogenic survival pathways with greater specificity and reduced toxicity.81 As our understanding of these conformational landscapes deepens, it paves the way for more refined, mechanism-based cancer therapeutics. This evidence concerns the gene CDC37 and cancer.